These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26597302)

  • 21. Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.
    Hansen AR; Cook N; Ricci MS; Razak A; Le Tourneau C; McKeever K; Roskos L; Dixit R; Siu LL; Hinrichs MJ
    Oncologist; 2015 Jun; 20(6):653-9. PubMed ID: 25964306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.
    Bullock JM; Lin T; Bilic S
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S105-S115. PubMed ID: 28921642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
    Fox E; Maris JM; Widemann BC; Goodspeed W; Goodwin A; Kromplewski M; Fouts ME; Medina D; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM
    Clin Cancer Res; 2008 Feb; 14(4):1111-5. PubMed ID: 18281544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing-Challenging the "more is better" dogma.
    Maués J; Loeser A; Cowden J; Johnson S; Carlson M; Lee S
    Clin Trials; 2024 Jun; 21(3):358-362. PubMed ID: 38385314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
    Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
    Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing benefit/risk in oncology: Review of post-marketing dose optimization and reflections on the road ahead.
    Soltantabar P; Lon HK; Parivar K; Wang DD; Elmeliegy M
    Crit Rev Oncol Hematol; 2023 Feb; 182():103913. PubMed ID: 36681205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
    Shapiro GI; Rodon J; Bedell C; Kwak EL; Baselga J; Braña I; Pandya SS; Scheffold C; Laird AD; Nguyen LT; Xu Y; Egile C; Edelman G
    Clin Cancer Res; 2014 Jan; 20(1):233-45. PubMed ID: 24166903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dose finding methods for targeted agents: new perspectives].
    Paoletti X; Postel-Vinay S; Servois V; Doussau A; Ollivier L; Le Tourneau C
    Bull Cancer; 2010 Dec; 97(12):1485-95. PubMed ID: 21220226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
    Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI
    Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
    Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
    Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
    Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.
    Papadopoulos KP; Kelley RK; Tolcher AW; Razak AR; Van Loon K; Patnaik A; Bedard PL; Alfaro AA; Beeram M; Adriaens L; Brownstein CM; Lowy I; Kostic A; Trail PA; Gao B; DiCioccio AT; Siu LL
    Clin Cancer Res; 2016 Mar; 22(6):1348-55. PubMed ID: 26490310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics.
    Mittapalli RK; Guo C; Drescher SK; Yin D
    Cancer Chemother Pharmacol; 2022 Sep; 90(3):207-216. PubMed ID: 35965268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
    Castaneda C; Meadows KL; Truax R; Morse MA; Kaufmann SH; Petros WP; Zhu Y; Statkevich P; Cutler DL; Hurwitz HI
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):455-63. PubMed ID: 20972873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.
    Gordon MS; Ilaria R; de Alwis DP; Mendelson DS; McKane S; Wagner MM; Look KY; LoRusso PM
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):21-7. PubMed ID: 23228983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
    Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
    Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
    J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.